The satiety factor oleoylethanolamide impacts hepatic lipid and glucose metabolism in goldfish
- 254 Downloads
Oleoylethanolamide (OEA) is an acylethanolamide synthesized mainly in the gastrointestinal tract with known effects in mammals on food intake and body mass through activation of peroxisome proliferator-activated receptor type α (PPARα). Since we previously demonstrated that acute treatment with OEA in goldfish resulted in decreased food intake and locomotor activity, as in mammals, we hypothesize that OEA would be involved in the control of energy metabolism in fish. Therefore, we assessed the effects of acute (for 6 h) and chronic (for 11 days) treatments with OEA (5 µg g−1 body mass) on metabolite concentrations and enzyme activities related to glucose and lipid metabolism in liver of goldfish (Carassius auratus). In the chronic treatment, OEA impairs the increase in body mass and reduces locomotor activity, without any signs of stress. The lipolytic capacity in liver decreased after both acute and chronic OEA treatments, whereas lipogenic capacity increased after acute and decreased after chronic treatment with OEA. These results are different from those observed to date in mammalian adipose tissue, but not so different from those known in liver, and might be attributed to the absence of changes in the expression of pparα, and/or to the increase in the expression of the clock gene bmal1a after chronic OEA treatment. As for glucose metabolism, a clear decrease in the capacity of hepatic tissue to use glucose was observed in OEA-treated fish. These results support an important role for OEA in the regulation of liver lipid and glucose metabolism, and could relate to the metabolic changes associated with circadian activity and the regulation of food intake in fish.
KeywordsOleoylethanolamide (OEA) Goldfish Liver Lipid metabolism Glucose metabolism Body mass
This study was supported by Spanish Ministerio de Economía y Competitividad (MINECO) research grant (AGL2013-46448-C3-2-R) to M.J.D, and by MINECO and European Fund for Regional Development research grant (AGL2013-46448-C3-1-R and FEDER) to J.L.S. M.G-B. and C.V. were recipients of predoctoral fellowship from MINECO (BES-2014-068103) and Universidade de Vigo, respectively.
- Decara JM, Romero-Cuevas M, Rivera P, Macías-González M, Vida M, Pavón FJ, Serrano A, Cano C, Fresno N, Pérez-Fernández R, Rodríguez de Fonseca F, Suárez J (2012) Elaidyl-sulfamide, an oleoylethanolamide-modelled PPARα agonist, reduces body weight gain and plasma cholesterol in rats. Dis Models Mech 5:660–670CrossRefGoogle Scholar
- González-Yanes C, Serrano A, Bermúdez-Silva FJ, Hernández-Domínguez M, Páez-Ochoa MA, Rodríguez de Fonseca F, Sánchez-Margalet V (2005) Oleoylethanolamide impairs glucose tolerance and inhibits insulin-stimulated glucose uptake in rat adipocytes through p38 and JNK MAPK pathways. Am J Physiol Endocrinol Metab 289:E923–E929CrossRefPubMedGoogle Scholar
- Hernández-Pérez J, Míguez JM, Librán-Pérez M, Otero-Rodiño C, Naderi F, Soengas JL, López-Patiño MA (2015) Daily rhythms in activity and mRNA abundance of enzymes involved in glucose and lipid metabolism in liver of rainbow trout, Oncorhynchus mykiss. Influence of light and food availability. Chronobiol Int 32:1391–1408CrossRefPubMedGoogle Scholar
- Keppler D, Decker K (1974) Glycogen determination with amyloglucosidase. In: Bergmeyer HU (ed) Methods of enzymatic analysis. Academic Press, New York, pp 1127–1131Google Scholar
- Librán-Pérez M, Polakof S, López-Patiño MA, Míguez JM, Soengas JL (2012) Evidence of a metabolic fatty-acid sensing system in the hypothalamus and Brockmann bodies of rainbow trout: implications in food intake regulation. Am J Physiol Regul Integr Comp Physiol 302:R1340–R1350CrossRefPubMedGoogle Scholar
- Romano A, Soares Potes C, Tempesta B, Cassano T, Cuomo V, Lutz T, Gaetani S (2013) Hindbrain noradrenergic input to the hypothalamic PVN mediates the activation of oxytocinergic neurons induced by the satiety factor oleoylethanolamide. Am J Physiol Endocrinol Metab 305:E1266–E1273CrossRefPubMedGoogle Scholar
- Serrano A, Del Arco I, Pavón FJ, Macías M, Perez-Valero V, Rodríguez de Fonseca F (2008) The cannabinoid CB1 receptor antagonist SR141716A (Rimonabant) enhances the metabolic benefits of long-term treatment with oleoylethanolamide in Zucker rats. Neuropharmacology 54:226–234CrossRefPubMedGoogle Scholar
- Shimba S, Ogawa T, Hitosugi S, Ichihashi Y, Nakadaira Y, Kobayashi M, Tezuka M, Kosuge Y, Ishige K, Ito Y, Komiyama K, Okamatsu-Ogura Y, Kimura K, Saito M (2011) Deficient of a clock gene, brain and muscle Arnt-Like Protein-1 (BMAL1), induces dyslipidemia and ectopic fat formation. PLoS One 6:e325231CrossRefGoogle Scholar
- Suárez J, Rivera P, Arrabal S, Crespillo A, Serrano A, Baixeras E, Pavón FJ, Cifuentes M, Nogueiras R, Ballesteros J, Diéguez C, Rodríguez de Fonseca F (2014) Oleoylethanolamide enhances β-adrenergic-mediated thermogenesis and white-to-brown adipocyte phenotype in epididymal white adipose tissue in rat. Dis Models Mech 7:129–141CrossRefGoogle Scholar